United States Market Report for Orthopedic Cell Therapy 2017 – Research and Markets – Business Wire (press release)

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Market Report for Orthopedic Cell Therapy 2017 - MedCore" report to their offering.

There has been much greater interest in bone marrow concentration for use in spinal fusions compared to platelet-rich plasma. The platelet-rich plasma market, on the other hand, is expanding into soft tissue indications. While bone graft substitutes can be soaked in PRP or bone marrow concentrate as an application, the most rapidly growing application, especially for platelet-rich plasma, is for injectables. Such products are directly injected into the site, for example, in a ligament repair or wound operation.

Competition over price is the reason the market values for these segments are not growing as quickly as might be expected. Arthrex significantly brought down the ASP for the market when they introduced their ACP platelet concentration system, but prices have now largely stabilized in the PRP segment. Test-tube-based products allow for concentration of smaller volumes; these systems reduce ASP further as customers can shift away from higher ASP disposable bucket products.

Key Topics Covered:

1. Research Methodology

2. Disease Overview

2.1 Basic Anatomy

2.2 Disease Pathology And Disorders

2.3 Patient Demographics

3. Product Assessment

3.1 Product Portfolios

3.2 Regulatory Issues And Recalls

3.3 Clinical Trials

4. Orthopedic Cell Therapy Market

4.1 Introduction

4.2 Market Overview

4.3 Market Analysis And Forecast

4.4 Drivers And Limiters

4.5 Competitive Market Share Analysis

Companies Mentioned

For more information about this report visit http://www.researchandmarkets.com/research/796hhz/us_market_report.

View original post here:
United States Market Report for Orthopedic Cell Therapy 2017 - Research and Markets - Business Wire (press release)

Stem Cell Therapy receives FDA Boost to enter the US Market – Labiotech.eu (blog)

TiGenix has receivedpositive feedback from the FDA on an improved global phase III trial protocol for its lead candidateCx601 for Crohns disease. This is expected tospeed up US approval.

TiGenix is a Belgian companydevelopingstem cell therapies. The biotech is currently pushing its lead candidateCx601to the market for the treatment ofcomplex perianal fistulas in Crohns disease patients. Cx601 recently revealedpositive resultsin a European phase III study.

Following these results, the company submitted a number of technical adjustments for itspivotal phase III study for Biologics License Application (BLA) in the US, which were now approved by the FDA and are expected to acceleratethe process to US marketing authorization.

TiGenix is wellknown for its productChondroCellect, which was the first cell therapyto reach approval on the European market for the repair of knee cartilage.After the companyrecently withdrew its market authorization for this product, due to a lack of reimbursement, the biotech is focusing on its new leadCx601.

Thisproduct, currently awaiting EMA approval, consists ofallogeneic expanded adipose-derived stem cells (eASC), which are indicated for the treatment ofperianal fistulas in Crohns disease. The therapeuticeffects of eASCs are based on immunomodulatory abilities of these stem cells, which canrestore immune balance by suppressing a variety of immune cell subsets and inducing the generation of regulatory T cells.

Areas of the colon commonly affected duringCrohns disease

The current approval from the FDA will allow TiGenix to file the BLAbased on the efficacy and safety follow-up of patients at week 24, instead of week 52.The FDA has also agreed to accept fewer patients than originally planned in the study and endorsed a broader target population that will ultimately facilitate the recruitment process.

We believe that this revised protocol will allow us to file for approval one year earlier than we had originally plannedconcludedMaria Pascual, VP Regulatory Affairs & Corporate Quality of TiGenix

The current amendments will allow TiGenix to push its therapyto the US market even faster, which might pivotal for the company in light of its financial situation. After its shares had reached a low of22 cents back in 2013, the share price is currently still under 1. Withits low 34M IPO on Nasdaq in the end of last year, its market cap is stillonly at 191M. A low sum for a late stage clinical company.

As the EMAapproval forCx601 is expected soon, which will then be commercialized by Takeda, the company may actually be underestimated. The biotech recently started a new Phase Ib/IIa trial to testCx611 as a treatment for sepsis in patients with pneumonia.

Asecond platform consisting of transplanted allogeneic cardiac stem cells (AlloCSC)is currently in Phase II for acute myocardial infarction. It seems like TiGenix is definitely clinging toits position as one of the pioneers in stem cell-based therapies.

Images via shutterstock.com / CI Photos and CC 3.0 /RicHard-59

Originally posted here:
Stem Cell Therapy receives FDA Boost to enter the US Market - Labiotech.eu (blog)

Stem Cell Therapy: Modern Solution to Joint Pain Relief – PR Newswire (press release)

PLAINVIEW, N.Y., March 6, 2017 /PRNewswire/ -- Board certified surgeon Dr. Andrew J. Rochman promotes the specialized treatment of Stem Cell Therapy in his private practice in Plainview, NY. The recent wave of positive response from its ability to target a growing number of health conditions has brought increased attention and demand from pain sufferers everywhere- including the Long Island area.

As of the fall of 2016, Dr. Rochman officially opened the Cell Therapy Center of NY (CTCNY) where he focuses on the treatment of osteoarthritis & rheumatoid arthritis, eroded cartilage and joint issues like tennis elbow, jumpers knee and golf elbow. He dedicated his practice to the large population suffering from musculoskeletal damage arising from sports injuries or the wear and tear from aging. "We are always seeking a safer and more effective alternative to surgery to battle physiological symptoms with the hopes of giving patients a pain-free life."

Dr. Rochman underwent extensive training from U.S. Stem Cell, Inc. (Sunrise, FLA) - a center for the development of effective cell technologies recognized for treating a variety of diseases and injuries. U.S. Stem Cell's discoveries include multiple cell therapies in various stages of development that repair damaged tissue due to injury or disease. Chief Science Officer Kristin C. Comella, expert in regenerative medicine with a focus on adipose derived stem cells, pioneered stem cell therapies derived from various sources including cord blood, bone marrow and muscle. "By harnessing the body's own healing potential, we may be able to reverse damaged tissue to normal function.... stem cells have the ability to form many types of tissues like bone, cartilage, muscle and even help to reverse some effects that have been caused by damaged tissue," states Ms. Comella.

Dr. Rochman's treatment center has recently seen an influx of patients from Long Island's large athletic and fitness community. President of the Wildwood Warriors triathlon team, John Graziano is one of the many joint and back pain sufferers from sports injuries seeking this alternative pain treatment. "In the world of triathlon, I train- I race- and I live with pain and lots of it!"

"The potential here is limitless," states Dr. Rochman. "It's actually a simple yet unique form of therapy with the possibilities of doing miraculous things. We found out within the past several years that human beings have stem cells in every tissue of their body and they actually live around the blood vessels." Today's stem cell therapy has been shown to manage and target a wide span of healing possibilities from blood cell diseases to cardiac disorders to autoimmune diseases. "So what we can do now is to extract fat cells from the belly or bone marrow cells and isolate the cells from those damaged tissues... perhaps in the future we can utilize this process to target neurological diseases, heart diseases... and we don't even know where it ends," says Dr. Rochman.

Dr. Andrew J. Rochman is a native New Yorker and a board-certified surgeon. He is a graduate of Colgate University and received his formal medical training from Nordestana University. He is an active member of the American Medical Association, the Medical Society of the State of New York, Nassau County Medical Society and the American College of Phlebology. Dr. Rochman manages several practices in specialized studies such as advanced vein therapy and gallbladder surgery. His current certification is with U.S. Stem Cell, Inc. specializing in cardiovascular treatment through stem cell technology. The Cell Therapy Center of NY is located at 700 Old Country Road, Suite 205 Plainview, NY. For more information, visit: http://www.celltherapycenterny.com or call 516-280-1333.

Media contact: Lennard Gettz 148804@email4pr.com 631-553-8748

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stem-cell-therapy-modern-solution-to-joint-pain-relief-300417654.html

SOURCE Cell Therapy Center of NY

Home

Excerpt from:
Stem Cell Therapy: Modern Solution to Joint Pain Relief - PR Newswire (press release)

Ingeneron Gets $20M From Sanford Health For Stem Cell Treatment … – Xconomy

Xconomy Texas

HoustonIngeneron, a Houston-based developer of a stem cell-based technology, announced Monday that it has raised $20 million from strategic partner Sanford Health.

Ingeneron is developing a stem cell-based system meant to help patients recover from wounds and orthopedic ailments like a torn shoulder rotator cuff. In total, the company has raised $38 million from unspecified family offices and high net-worth individuals in both the United States and Germany.

Sanford Health, a large hospital chain based in Sioux Falls, SD, is conducting a small, 18-patient safety study of Ingenerons system, known as Transpose RT, being used to heal orthopedic ailments like torn shoulder rotator cuffs.Results are expected around the third quarter of this year, says Ron Stubbers, who was appointed the companys president following an executive shakeup last month. (Stubbers was previously InGenerons vice president of operations.)

Sanford Health has been involved with regenerative medicine for a long time, so this [investment] is continuing in that vein for them, Stubbers says.

Assuming all goes well, Ingeneron will have to run a much larger studylikely in 2018 and run into2019to test the products effectiveness and get it to market in the U.S., Stubbers says. Transpose RTis already sold in Europe for chronic wounds like venous ulcers. Ingeneron has also a second IDE in order to conduct a separate trial this spring to test the systems feasibility in healingchronic wounds.

Patients with torn or damaged rotator cuffs typically get a cortisone injection, but that just reduces inflammation and pain. It doesnt actually heal the tendon, as Ingenerons technology is meant to do.

Stubbers says Ingeneron has created a machine about the size of a table-top centrifuge that isolates and extracts stem cells taken from a patients fat tissue. Those cells are then injected into a patient, where theyre meant to help heal damaged tissue.

Ingeneron was founded in 2006 by Eckhard Alt, the companys chairman and a professor of medicine at the University of Texas MD Anderson Cancer Center, Tulane University in New Orleans, LA, and Technische Universitt in Munich. (Ingeneron also has an office in Munich.)

Although Ingenerons primary focus is orthopedic treatments and wound care, the company does have an animal health division. Its technology was used five years ago, for instance, at the Houston Zoo to treat a Malayan tiger with large bone chips in his right elbow and a female leopard with a bad limp from an elbow injury.According to a story in the Houson Chronicle, Pandu the tiger saw an improved quality of life from the procedure. Ultimately, both the elderly leopard and the 16-year-old tiger had to be euthanized in 2014 and 2015.

Angela Shah is the editor of Xconomy Texas. She can be reached at ashah@xconomy.com or (214) 793-5763.

Read this article:
Ingeneron Gets $20M From Sanford Health For Stem Cell Treatment ... - Xconomy

Sanford Health invests up to $20M in stem cell device company – MedCity News


MedCity News
Sanford Health invests up to $20M in stem cell device company
MedCity News
... adipose-derived stem cells. In a separate call, Rich Adcock, chief innovation officer for Sanford Health, said his organization has a progressive research agenda that goes above and beyond patient care. With some 45 hospitals and nearly 300 clinics ...

and more »

Excerpt from:
Sanford Health invests up to $20M in stem cell device company - MedCity News

Researchers Engineer Enforcer Cells That Will Take out Lethal Bacteria – Big Think

Bacteria and antibiotics have been in an arms race since the drugs were invented. But for economic reasons, fewer and fewer of these drugs are being developed today, while the fear of antibiotic-resistant bacteria is ever-growing. This, and the potential threat of a bioterror attack, where say an epidemic-causing bacteria is released into the general population, makes the need for countermeasures obvious. Johns Hopkins researchers have come up with a new way to eliminate dangerous bacteria, using beefed up cells who seek out and destroy dangerous pathogens, all on their own.

Researchers from the John Hopkins Whiting School of Engineering and the School of Medicine teamed up on this four-year project. They received a grant of $5.7 million, awarded by the federal agency DARPA (Defense Advanced Research Projects Agency). The point of the study is to create a biocontrol system that can send out single-cell enforcers to find and eliminate certain pathogens. Researchers will program amoeba cells to do so, each one micron long, about one-tenth the width of a human hair.

These amoeba are independent and travel on their own surfaces--meaning they can get potentially deadly pathogens wherever they may be. In the event they are needed, they would be emitted through a spray. As a first step, scientists hope to program the cells to go after the bacteria which causes Legionnaires disease.

It could also be used to target Pseudomonas aeruginosa, a dangerous, potentially deadly, treatment-resistant strain of pneumonia. In another scenario, specially engineered amoeba cells are unleashed by health officials if an outbreak occurs. There are other uses too. They could sterilize instruments, and studying them may even reap benefits for cancer research.

So whats DARPAs interest? These biochemical warriors may someday help dampen down or even counteract a bioterror attack. They could also be used to render contaminated soil harmless. The innovation here is that each cellular soldier is self-directed. It does not depend on an outside human operator. Principal investigator Pablo A. Iglesias likened it to a self-driving car. Iglesias is a professor of electrical and computer engineering at Johns Hopkins.

Amoebas.By C.G. Ehrenberg (Die Infusionthierchen, 1830) [Public domain], via Wikimedia Commons

Just as cruise control slows down or speeds up a car, Iglesias said, In a similar way, the biocontrol systems were developing must be able to sense where the pathogens are, move their cells toward the bacterial targets, and then engulf them to prevent infections among people who might otherwise be exposed to the harmful microbes.

Iglesias started looking into biocontrol systems 15 years ago. To develop this particular type of synthetic biology, he is teaming up with four colleagues at the school of medicine. Each is a biological chemistry expert. Douglas N. Robinson, a professor of cell biology is on the team. He likened what these amoebas do to bacteria to what humans do when they encounter freshly baked cookies. They seek to gorge themselves unabashedly.

Though the technique has a lot of potential, Iglesias admitted to the Baltimore Sun, that past experiments in the field havent actually gone very well. "People manage to do things but it takes huge amounts of effort and it's more or less random, he said. There has to be a lot of iterations before it works." Other experts say, this teams efforts are heartening, particularly due to the growing menace of antibiotic-resistant bacteria.

Researchers are using amoeba cells called Dictyostelium discoideum in their experiments. This species is commonly studied. It can be found in the damp soil of riverbeds. These microbes surround bacteria and devour them. Turns out the bacteria let off a biochemical scent that the amoeba, using a specific type of receptor, pick up.

Robinson said that their experiments must adhere to the strictest operating protocols, lest such amoeba escape into the environment and wreak havoc. If this project bears fruit, researchers believe theyll have a new tool to fight infection in hospitals, and protect society against bioterror and ecological disasters. So far, scientists are targeting only pathogens lurking outside the human body. In this contract, we are not targeting bacteria in human blood, Iglesias said. But the hope is that the techniques we develop would ultimately be useful for that.

To learn more about synthetic biology, click here:

Continue reading here:
Researchers Engineer Enforcer Cells That Will Take out Lethal Bacteria - Big Think

Stem Cell Therapy – Premier Regenerative Stem Cell

The Re-Brand Premier Regenerative Stem Cell and Wellness Centers, recently rebranded their business from Premier Stem Cell Institute, in response to expanding locations, technology, and treatments. This move reflects the growth and success this company has undergone recently and goals for the future.

PRSC and Wellness Centers President, Kandace Stolz said, This rebrand is the culmination of the years of work weve put into stem cell medicine. Were growing and healing more patients than we ever have before, this new name reflects those accomplishments and gives us room grow. We are so thrilled for this move and cant wait to do even more for our patients going forward.

Premier Regenerative Stem Cell and Wellness Centers will continue to partner with the NFL Alumni Association and treat current and former professional athletes. PRSC remains dedicated to studying stem cell treatment by collecting and tracking data to further stem cell progress and maximize results for all patients. PRSCs commitment to being a leader in stem cell and regenerative medicine is unwavering and will continue to innovate and learn to heal and improve the quality of life for all patients.

About Premier Regenerative Stem Cell and Wellness Centers: PRSC is a leading research and treatment facility in Colorado, providing innovative medicine and therapies for those in pain by harnessing the bodys own natural healing power of stem cells. As team of cutting-edge medical experts, PRSC is dedicated to treating patients by using their own stem cells to heal, improve quality of life, and battle the acute pain of chronic illnesses. Premier Regenerative Stem Cell and Wellness Center locations include Loveland Colorado, Dallas Texas, St. Louis, Missouri, and Jacksonville, Florida. PRSC has plans to expand to other major cities across the United States in the near future.

Here is the original post:
Stem Cell Therapy - Premier Regenerative Stem Cell

Hospital group invests $20M in stem cell therapy biotech – FierceBiotech

Hospital group Sanford Health has invested $20 million in InGeneron to support clinical trials of a stem cell regenerative medicine. The Series D gives Sanford a financial stake in an adipose-derived stem cell therapy it is testing in a clinical trial at its network of healthcare facilities.

InGeneron began working with Sanford on an 18-person trial of its stem cell injection in patients with partial thickness rotator cuff tears around the turn of the year. And the network of 45 hospitals and close to 300 clinics has now tightened its ties to InGeneron by investing $20 million in the Houston, TX-based regenerative medicine company. InGeneron sees benefits in strengthening its relationship with Sanford.

This significant investment demonstrates Sanfords commitment to be an active participant in InGeneron as well as being our clinical trial site of choice. Our joint efforts will enable the company to make regenerative cell therapies available to clinical practice and to establish a leading position in the application of adipose-derived regenerative cells, InGeneron President Ron Stubbers said in a statement.

Sanford runs the two trial sites that are enrolling patients in the aforementioned 18-person trial. Both sites specialize in orthopedics and sports medicine. Rotator cuff injuries are associated with overhead sports, such as baseball and tennis. The healthcare system is presenting its close involvement with InGeneron as a positive for the patients it serves because it facilitates early access to an experimental therapy.

The treatment entails processing adipose tissue harvested during liposuction to create a mixture containing stem cells and nutrients. This mixture is injected into the site of the injury. In the trial, one-third of participants will form a control arm and receive a cortisone injection instead of stem cells.

The exec team tells FierceBiotech that the first patients were enrolled in the feasibility trial for rotator cuff tendinopathy in January, with U.S. regulatory market approval "anticipated in 2020."

InGeneron last raised money last year through a $4.5 million seed round. That financing, which came 10 years after InGeneron was founded, followed studies of the companys cell therapies in knee surgeries. InGeneron also makes biomedical equipment for collecting and processing adipose tissue.

The biotech has and its subsidiaries on both sides of the Atlantic has a team of 30 people, and has raised $38 million to date.

Continued here:
Hospital group invests $20M in stem cell therapy biotech - FierceBiotech

Stem Cell Therapy An Option For ENC Patients – Public Radio East

Stem cell therapy is a quickly advancing treatment being used across the country. Now, its becoming more prevalent in eastern North Carolina to those living with chronic pain an alternative to surgery. The minimally invasive procedure is showing results in alleviating back, knee, hip and shoulder pain. Though stem cell therapy is classified by the Food and Drug Administration as experimental, patients say theyre finding relief. Meet New Bern resident and a local endodontist Dr. Donnie Luper. He was skeptical of the procedure at first.

How did you know what those stem cells were going to differentiate into? I mean was I going to grow a foot out of my shoulder or something like that?

Luper tore his rotator cuff 25 years ago during a tubing incident on the Trent River. A subsequent fall during a golf trip in 2015 sent him to a specialist.

I went to see a shoulder surgeon in Richmond. He told me that he didnt think it was a complete tear of my rotator cuff, that I could probably have a minor surgical procedure done and I asked him about stem cell.

After talking with a friend who opted for stem cell treatment for her knee pain, Luper decided to find out more.

My option was if I would have had that shoulder surgery and they had do that bicep tendon repair, I mean I would have been in a sling for six weeks and probably not working for three months.

According to the Food and Drug Administration, stem cells sometimes called the bodys master cells - have the ability to divide and develop into many different cell types. Each new cell has the potential to remain a stem cell or become another type of cell, such as a nerve cell, a skin cell, or a red blood cell. They may also help repair the body by dividing to replenish cells that are damaged by disease, injury or normal wear. Parkinsons disease, spinal cord injuries, damaged organs and cancer could all be possibly treated with the use of stem cells, but more research is needed. Dr. Angelo Tellis is the owner/physician of Aegean Medical, which provides stem cell therapy to patients in Cary, Jacksonville, Morehead City and New Bern.

The adult stem cells we call multipotent stem cells so they can only differentiate into very specific or certain kinds of tissue. Whereas the embryonic stem cells we call pluripotent and can become a variety, almost any tissue. But I only deal with adult stem cells, theyre found to be more useful in clinical applications.

Dr. Tellis says adult stem cells are more responsive to growing tissue in very specific locations. When patients go into Dr. Tellis office for the two hour procedure, he starts by numbing an area of the abdomen and performing liposuction to collect one or two syringes of body fat.

Stem cells can be found in a lot of different tissues throughout the body, but theyre actually in one of the highest concentrations in your own body fat.

The stem cell sample is combined with platelet rich plasma or PRP collected through a blood draw.

That has a lot of the chemical signals and messengers that activate stem cells. So Ill typically combine that with some of the stem cells collected from the body fat and then go under x-ray guidance and put it exactly in the targeted location where we want to create that healing process.

Soreness and stiffness can be expected immediately following the procedure and for about a week after. Dr. Tellis says the results tend to improve with time, taking about three to six months for full recovery. This was Lupers experience in 2016.

Really didnt have to take any pain medications. The joint was really sore over the weekend just because of the injection of the fluid there and after that, I had a small amount of discomfort, but nothing I really had to take medication for.

After three months, Luper says he felt 90 percent better. But he decided to get a second opinion from a shoulder surgeon.

And he told me he thought the stem cells had done a lot but that I still had one little bone spur that was rubbing against the muscle and constantly tearing the little bit of the muscle.

After surgery, Luper says his left shoulder started feeling significantly better in about a month. He was also able to return to one of his favorite pastimes golf. While surgery helped eliminate all of his pain, Luper believes stem cells helped regenerate tissue that was damaged years ago.

He said my rotator cuff muscle didnt even look like it had been torn. I actually tore that, Im sixty now, and I actually tore that when I was 34, 35 tubing on the river and I had to do physical therapy for about three months, but he said he saw absolutely no evidence that Id ever had a rotator cuff tear.

Even though some have found relief and possibly a cure through stem cell therapy, the Food and Drug Administration has not approved any stem cell-based products for use, other than HEMACORD (HE-muh-cord). According to their website, the use of stem cells raises safety concerns such as excessive cell growth, the development of tumors as well as cells migrating from the site of administration and differentiating into inappropriate cell types. And then, theres the cost of the procedure, which is not covered by insurance. The price for the treatment ranges from $2,500 to $5,000. But for those who want to avoid major surgery and the downtime associated with recovery, the risk and cost may be worth it.

If Id have surgery, my deductible would have been that because I have an out-of-pocket max. And I would want to do anything to avoid surgery, especially something that would keep me out of work for three months.

The FDA recommends that consumers interested in stem cell therapy should start a conversation with their doctor about the potential risk to benefit ratio. In addition to Aegean Medical, Advanced Health and Physical Medicine in Greenville and Regenerative Medicine Clinic of Wilmington also provide stem cell therapy in eastern North Carolina.

The rest is here:
Stem Cell Therapy An Option For ENC Patients - Public Radio East

Is Alzheimer’s treatment of injecting stem cells into the brain a breakthrough or quackery? – The Mercury News

More than eight years after he realized something was wrong, after, as he described it, My brain went

Whats the word? Foggy, Jack Sage finally said after several seconds of silently coaxing his synapses to fire.

More than eight years after his brain went foggy, four years after he was diagnosed with Alzheimers disease and two years since he began an innovative and extremely invasive therapy, Sage said he is being flooded by memories that seem new, or, at the very least, feel easier to retrieve. His daughter, Kate, thought Sage had suddenly begun to open up about his past because he knew his time was growing short.

He should not know who I am at this point, Kate said.

His doctor, Christopher Duma, hopes Jack Sage goes down in history as the one-man turning point in the treatment of Alzheimers disease, while others are skeptical about what Duma has done to Sages brain. Everyone agrees that Alzheimers disease is an exploding problem.

The California Alzheimers Disease Data Report from 2009 projected a 67 percent increase between 2015 and 2030 in residents in Los Angeles, Orange, Riverside and San Bernardino counties living with Alzheimers disease up to 498,137. The same report references a study, between 2000 and 2004, in which 58 percent of the deaths among people 65 and older in California were attributed to Alzheimers disease. New numbers will be released Tuesday.

The Alzheimers Association reported that 610,000 Californians 65 or older had the disease in 2016, and it estimated increases to 690,000 by 2020 and 840,000 by 2025.

On a cool recent night, Sage, a handsome, fit, 82-year-old, sat next to his wife Gloria talking about his children (It is significant that Sage remembers their names James, 46, Kate, 50, and Kelly, 56), recalling when he and Gloria moved into the Newport Beach house with a view of the Pacific Ocean (1990), laughing about their first date at the Bel-Air Country Club (1979), recounting his years as a labor negotiator and executive for Del Monte, Allied Chemical and Continental Airlines (1970s and 60s) and going all the way back to the jack hammering he did in the nickel mines (mid-1950s) in Northern Ontario, Canada.

At this point in his illness, his doctor said he should be having more trouble remembering the perilous tunnels of the Sudbury nickel mine.

You drill into the granite, Sage said. You put dynamite in the rock. You dynamite it. Then you shovel out whats left.

And mining, you might say, is what is happening in Jack Sages brain.

Sages series of recollections, including his exploits on the golf course in Indian Wells where he has a second home and plays several days a week flashbacks representing the three main components of long-term memory: semantic (recalling the meaning of words), episodic (recalling autobiographic milestones) and procedural (recalling how to accomplish tasks) prompted a grin from Duma, the brain surgeon who, for $10,000 per treatment and without insurance coverage, cut a hole in the back of Sages head and injected a stem cell serum that had been sucked out of Sages love handles.

Is this the Alzheimers breakthrough the world has been waiting for? Or, is this unproven medical procedure what University of Minnesota bioethicist Leigh Turner calls quackery and flimflam? Is this an unsafe, money-grab it is being conducted outside the approval process of the Food and Drug Administration preying on the most vulnerable among us?

Turner has written extensively and critically about the Cell Surgical Network (CSN), for which Duma, whose home hospital is Hoag in Newport Beach, is listed as a network physician. The CSN promotes the stem cell revolution, which its literature claims, is an appropriate treatment for people suffering from a variety of inflammatory and degenerative conditions in other words, for cancer, diabetes, bad knees and hips as well as multiple uses in cosmetic surgery.

You dont just start dumping things into peoples brains, Turner said. The problem is people may spend a lot of money and find there is no benefit. He (Duma) is exposing people to serious harm. Fat cells dont belong in peoples brains.

Sage is the first patient in Phase I of a clinical study officially called Intracerebroventricular injection of autologous abdominal fat-derived, non-genetically altered stem cells. Sage was the first Alzheimers patient anywhere to have his own liposuctioned cells injected directly into his brain. He has received eight injections (about two months apart) since November 2014.

Duma quickly offers a qualifier. It is far too early to tell if what he has done to Sage will indeed change the world. He said Sage and, later, 19 other patients have not been harmed by the procedure, and that safety is the only criteria in Phase I. Whether the treatment is effective is a question for Phase II, for which Duma is hoping to attract private funding. Also, he wrote a letter to the national Alzheimers Association asking for $700,000 to continue his work. He was instructed to apply officially later this year. If he gets the grant, the fees for his patients would be waived.

Early in the process, Duma is excited by Sages results.

Sages most recent cognition scores have risen from 45 on the 100-point Memory Performance Index in March 2015 to 54 in September 2015. The volume of his hippocampus the memory center of the brain has grown from the fifth percentile before his first treatment to the 28th percentile after his fourth treatment to the 48th percentile after his eighth treatment.

My golf game is getting better, said Sage, who, heart permitting, plays several times per week. Sages brain isnt his only problem. He has a long history of heart ailments that have required the insertion of 12 stents to keep his arteries open.

You cant make a global conclusion based on one patient, but its a huge turning point, Duma said with the confidence of someone who probes brains for a living.

Duma is somewhat of a maverick in the medical world, a brain surgeon who regularly shuns a scalpel for the gamma knife, a futuristic laser for removing brain tumors. He is known outside the operating room for playing keyboards in bands that specialize in 1970s-era covers of groups such as Genesis, Yes and Emerson, Lake and Palmer. As a child, he was a classmate of John F. Kennedy Jr. at The Browning School in New York City. We called him John John, Duma said.

Duma realizes he will face opposition to his stem cell/brain injection therapy. But, as in all breakthroughs, someone has to be first.

I could have harmed people, he said. I took an enormous leap.

Not much hope

Alzheimers patients dont get better.

They get diagnosed, lose their dignity and die.

The speed at which death occurs is the only variable.

In the depressing world of Alzheimers treatment, Sage and Duma represent equal parts hope and skepticism. The Orange County Register contacted universities and research centers across the country, including Stanford, Harvard, Duke, Florida International, UC Davis, and some of the interview requests were denied while other calls were not returned. Very few medical experts want to talk about the combination of stem cells and Alzheimers disease, apparently because they know so little about it.

An Alzheimers patient improving because of therapy? Im hopeful its true. Im hopeful its true for all patients, said Joshua Grill, the co-director of the Memory Impairments Neurological Disorders (MIND) institute at UC Irvine. We are in dire need.

But, Grill continued, One study does not a revolution make. Ive never read anything about this (Dumas work), and I dont know what science is behind it.

Dean Hartley, Director of Science Initiatives at the Alzheimers Association, knew about Dumas work.

This is new territory, Hartley said. But with one patient, No, you cannot say this is a game-changer.

Hartley said many studies fail at the Phase II level, where more and more people are exposed to the therapy.

Still, Hartley said Dumas work is encouraging.

We want to see things like this happen, Hartley said.

Its not as if Duma is conducting his research in secret. He spoke about his study in public forums twice last year Sept. 28 at the Congress of Neurological Surgeons in San Diego, and Oct. 1 at the International Society for Cellular Therapy in Memphis.

Duma said he is nearly finished writing a paper about his work that he hopes will be published in a peer-reviewed journal.

The stem cell idea

In 1993, Christopher Duma was working at Good Samaritan Hospital in Los Angeles when he and his colleagues began injecting stem cells into the brains of patients with Parkinsons disease. They were making some progress, he said, but politics intervened. Some of the stem cells they were using came from aborted fetuses. Pressure from anti-abortion groups shut that program down.

Fifteen years later, Duma was assisting plastic surgeon Michael Elam on a face-lift on a Parkinsons patient when Elam said, We need to talk about stem cells.

Elam introduced Duma to Drs. Mark Berman and Elliot Lander, the founders of the Cell Surgical Network.

Berman and Lander had been separating stem cells from fat by using a centrifuge (which they own the patent for) and injecting them into knees and hips and other places where injuries had occurred. Their work had passed an Institutional Review Board after 1,524 patients were treated with no adverse effects, Berman said.

If you want to repair an injury, Berman said, the best tissue is the stem cell.

In 2013, Duma suggested a new target for stem cell therapy: the brain.

Duma, with Berman, Lander and Elam as co-authors, tried to begin a study of brain/stem cell injections. But their first attempt at Institutional Review Board approval was denied because they hadnt done animal testing. So they got Dr. Oleg Kopyov at Cal State Northridge to conduct tests on rats.

With the help of Kopyovs work, Duma got Institutional Review Board approval. They chose not to take the usual next step FDA approval.

The Institutional Review Board was expecting us to go through the FDA, Lander said. But there are hundreds of obstructions. The FDA approval process usually takes between eight and 12 years, according to the online journal Medscape.com.

Duma said stem cells present a quandary for the FDA because stem cells are not a drug, and theyre not food. Clinics that take stem cells out of the body and put them back in without additives argue that they are exempt from FDA mandates.

We have been harvesting fat from abdomens and putting them in the brain during brain surgeries since the 1920s, Duma said. We do it nearly on every case for pituitary tumors, acoustic and skull base tumors and for conditions of spinal fluid leakage since the 1920s. If the FDA ruled that harvested autologous fat cannot be used in the brain, then it would change nearly a century of neurosurgical standard of care.

Someday, Duma said he hopes the FDA will recognize his work.

The work cant wait, he said.

The brave one

In August 2013, Jack Sage staggered into the office of Dr. William Shankle in Newport Beach.

Shankle, a renowned expert in cognitive disease he is the author of the Memory Performance Index that is used around the world diagnosed Sage with two problems: Alzheimers disease and hydrocephalus (fluid on the brain). Sage needed a shunt in his brain to drain the fluid and relieve the pressure.

So Shankle walked him down the hall (their offices are yards apart on the same floor in the same building) and introduced Sage to Christopher Duma, medical director of Hoag Hospitals Brain Tumor Program, and the surgeon who would put in the shunt.

Duma remembers that first meeting. Sage was in straight-line cognitive decline, Duma said.

Shankle would not grant an interview about Duma or his treatment. Shankle said he is wary of hocus pocus about Alzheimers disease without saying that Duma has done anything wrong. More than a decade ago, Shankle tried a surgical stem cell therapy on patients. He removed patients stem-cell-rich omentum, a fatty sheath covering the abdomen, cut open their skulls and stretched the omentum directly on their brain. Four of the six patients he studied had serious complications from the surgery.

The patients improved in cognitive tests, but the surgery was too much for them.

The method of delivering the treatment was radical (surgical transposition of the greater omentum to the surface of the brain while keeping the blood supply intact), Shankle wrote in an email. After showing that it really works, my goal was to never do the surgery again but find a different way of delivering these critical factors less invasively.

Sage was the patient Duma had been waiting for.

Jack was a man who was doomed, Duma said. He looked like classic Alzheimers. He had no ability to follow a train of thought. He was asking and re-asking the same questions. People like Jack are there, but theyre not there.

Sage was perfect for Duma for other reasons. He has always been a fitness nut cycling, tennis, golf, skiing and 10K runs were all part of his lifestyle. Kate Sage said he has been ordering salmon and spinach for dinner at restaurants for years.

Jack is the experimental model, Duma said. He is the brave one.

During two years of treatments, Sage has either maintained or slightly improved his cognitive health. He had a major heart attack in 2016, making his brain less of a cause for concern than his heart.

Kate said she doesnt know if Dumas treatment is working.

Its hard for me to say this is miraculous, Kate said.

She said she doesnt worry about his brain as much anymore.

Hes going to drop dead with some kind of a heart thing, she said. Hes not going to lose his memory.

Jack Sage

The tragedy of Alzheimers disease is that it not only steals the history that makes us who we are. It takes our skills, our beliefs, our independence, our ability to love.

So far, Jack Sage is still Jack Sage. Obviously, he doesnt know if he would be the same without Dumas treatments.

I can tell Im getting better and better, Sage said. Is that pure optimism? The Placebo Effect?

In January, Jack Sages drivers license came up for renewal. He said hes able to remember driving directions without problem. He still navigates the route from his home in Newport Beach to his other home in Indian Wells. But, he was required to pass the written test, and Sage feared he wouldnt be able to remember the complex rules of the road.

I was worried, he said.

But he passed, and his license was extended five years.

His improved memory, he said, sometimes catches him by surprise.

These memories come up when I dont even think about it, Sage said.

Sometimes, the memories take Sage places he doesnt want to go.

When he worked in the nickel mines in the 1950s, he and his first wife had a son.

His name was Mark, Sage said, speaking slowly as if the memory was bubbling up from depths he didnt want to consider. We rented a house with a playroom. My wife went shopping, and I was upstairs

I was working on my school work for McMaster University

Mark fell

we had a drainage basin inside the house

when I got to him, he was gone

Sage stopped talking as if flooded by new emotions over the death of his son.

We were distraught, he said. It was tough times for years.

In the murky world of Alzheimers therapy, Jack Sage is still mining.

Contact the writer: ksharon@scng.com

Visit link:
Is Alzheimer's treatment of injecting stem cells into the brain a breakthrough or quackery? - The Mercury News